Johnson & Johnson
Open
$238.37
Prev. Close
$238.49
High
$239.00
Low
$238.36
Market Snapshot
$571.15B
27.1
5.84
$88.82B
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. The company is headquartered in New Brunswick, New Jersey and currently employs 138,200 full-time employees. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
Johnson & Johnson's positive quarterly performance reflects strong investor confidence amid robust sales in its pharmaceuticals and consumer health divisions.
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. The company is headquartered in New Brunswick, New Jersey and currently employs 138,200 full-time employees. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
Recently from Cashu
Johnson & Johnson Advances Drug Development for Autoimmune and Oncological Conditions with Nipocalimab
Johnson & Johnson (Ticker: JNJ) makes strides in the healthcare industry with promising advances in its drug development pipeline, particularly with nipocalimab. Recent data from clinical trials showc…
TREMFYA® Approved: Johnson & Johnson’s Breakthrough in Psoriatic Arthritis Treatment
Johnson & Johnson (Ticker: JNJ) announces a significant milestone with the U.S. Food and Drug Administration's (FDA) approval of a supplemental Biologics License Application for its medication TREMFYA…
Johnson & Johnson Launches Innovative Shockwave C2 Aero Catheter for Cardiovascular Treatment Expansion
Johnson & Johnson (Ticker: JNJ) is advancing its portfolio in cardiovascular treatment through the recent launch of the Shockwave C2 Aero coronary intravascular lithotripsy catheter. This innovative d…
Johnson & Johnson Advances IBD Treatments with Promising New Therapies and Ongoing Research Initiatives
Johnson & Johnson (Ticker: JNJ) has recently announced significant advancements in the treatment of inflammatory bowel diseases (IBD), showcasing its commitment to addressing unmet medical needs in th…